Características clínicas del carcinoma hepatocelular en España. Comparación con el período 2008-2009 y análisis de las causas del diagnóstico fuera de cribado. Estudio de 686 casos en 73 centros

Lope, Carlos Rodríguez de; Reig, María; Matilla, Ana; Ferrer, María Teresa Martínez; Dueñas, E.; Mínguez, Beatriz; Castroagudı́n, J.F.; Ortiz, Inmaculada; Pascual, Sonia; Lledó, José Luis; Gallego, Adolfo; Arenas, Juan; Aracil, Carles; Forné, Montserrat; Muñoz, Carolina; Pons, Fernando; Sala, María; Iñarrairaegui, Mercedes; Martín‐Llahí, Marta; Garrè, C.; Rendón, Paloma; Fuentes, Javier; Crespo, Javier; Rodrı́guez, Manuel; Bruix, Jordi; Varela, Marı́a

doi:10.1016/j.medcli.2016.12.048

Cited by 17 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surveillance for HCC represents a major challenge in co-infected populations not only due to the complex nature of dual disease, but also because most guidelines are tailored towards mono-infected individuals at risk for HCC. In addition, recent studies show that ultrasound surveillance has a low performance for HCC in HBV or HCV individuals co-infected with HIV, with a suboptimal 43% rate of early-stage diagnosis, compared to 63%-71% found in studies on HIV-uninfected cohorts[ 73 , 74 ].…”

Section: Co-infections and Hccmentioning

confidence: 99%

Current impact of viral hepatitis on liver cancer development: The challenge remains

Mattos¹,

Debes

Boonstra

et al. 2021

WJG

View full text Add to dashboard Cite

Chronic infections due to hepatitis B and hepatitis C viruses are responsible for most cases of hepatocellular carcinoma (HCC) worldwide, and this association is likely to remain during the next decade. Moreover, viral hepatitis-related HCC imposes an important burden on public health in terms of disability-adjusted life years. In order to reduce such a burden, some major challenges must be faced. Universal vaccination against hepatitis B virus, especially in the neonatal period, is probably the most relevant primary preventive measure against the development of HCC. Moreover, considering the large adult population already infected with hepatitis B and C viruses, it is also imperative to identify these individuals to ensure their access to treatment. Both hepatitis B and C currently have highly effective therapies, which are able to diminish the risk of development of liver cancer. Finally, it is essential for individuals at high-risk of HCC to be included in surveillance programs, so that tumors are detected at an early stage. Patients with hepatitis B or C and advanced liver fibrosis or cirrhosis benefit from being followed in a surveillance program. As hepatitis B virus is oncogenic and capable of leading to liver cancer even in individuals with early stages of liver fibrosis, other high-risk groups of patients with hepatitis B are also candidates for surveillance. Considerable effort is required concerning these strategies in order to decrease the incidence and the mortality of viral hepatitis-related HCC.

show abstract

Section: Co-infections and Hccmentioning

confidence: 99%

Current impact of viral hepatitis on liver cancer development: The challenge remains

Mattos¹,

Debes

Boonstra

et al. 2021

WJG

View full text Add to dashboard Cite

show abstract

“…Early diagnosis and surgical treatment are the best option to manage liver cancer. However, only 20% to 30% of liver cancer patients can be diagnosed early according to the statistical data [3,4]. Most patients in the middle and late stages have to choose chemotherapy, radiotherapy, and interventional therapy, but those chemical drugs also damage normal liver tissues [5,6].…”

Section: Introductionmentioning

confidence: 99%

Sorafenib‐Loaded Long‐Circulating Nanoliposomes for Liver Cancer Therapy

Zhou

Jin

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

A type of sorafenib- (SOR-) loaded long-circulating nanoliposome was constructed, and the targeting performance and antitumor effects of the prepared liposome were evaluated in the present study. Polyethylene glycol- (PEG-) modified long-circulating nanoliposomes (LC-NPs) were designed and prepared using reverse evaporation, and the LC-NPs were used for delivering sorafenib (LC-PEG-SOR-NPs). Then, the anti-VEGFR antibody as a targeting moiety was chemically coupled with LC-PEG-SOR-NPs to form liver cancer-targeted nanoliposomes (anti-VEGFR-LC-PEG-SOR-NPs). The drug entrapment and loading efficiency were measured. And the cancer-targeting performance and therapeutic efficiency were evaluated both in vitro and in vivo. The anti-VEGFR-LC-PEG-SOR-NPs with an average of 119.8±4.2 nm showed a uniform spherical structure. The drug entrapment and loading efficiency were 92.5% and 18.5%, respectively. The killing efficiency of anti-VEGFR-LC-PEG-SOR-NPs was up to 18% after incubating with liver cancer cells for 72 h. Furthermore, the anti-VEGFR-LC-PEG-SOR-NPs could actively target at the tumor region and could efficiently inhibit tumor growth with negligible side effects. This newly designed nanoliposomes had desirable dispersibility, high drug entrapment efficiency, tumor targeting and therapeutic efficiency, and good safety. As a biocompatible nanocomposite, it was promising to become a novel and useful tumor-targeting nanodrug for liver cancer therapy.

show abstract

Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies

2020

View full text Add to dashboard Cite

Características clínicas del carcinoma hepatocelular en España. Comparación con el período 2008-2009 y análisis de las causas del diagnóstico fuera de cribado. Estudio de 686 casos en 73 centros

Cited by 17 publications

References 38 publications

Current impact of viral hepatitis on liver cancer development: The challenge remains

Current impact of viral hepatitis on liver cancer development: The challenge remains

Sorafenib‐Loaded Long‐Circulating Nanoliposomes for Liver Cancer Therapy

Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies

Contact Info

Product

Resources

About